BellBrook Labs of Madison, Wisconsin, develops innovative solutions to the technical problems which can slow drug discovery and development. The company uses a research and development-based business model in order to develop new technologies. BellBrook Labs currently markets two main product lines, Transcreener and Iuvo, which enable pharmaceutical firms to streamline the research process, reduce drug discovery costs, and cut the time required to find new therapies for deadly illnesses.
Working with faculty from top research universities, BellBrook Labs developed the Transcreener High Throughput Screening (HTS) Assay technology internally and has built a strong intellectual property platform around it. The assay allows researchers to detect the enzyme groups most commonly targeted by new drugs. The development team behind Transcreener created it to be accurate, easy to implement, and easy to automate.
Transcreener from BellBrook Labs uses a fluorescent tracer for direct detection of nucleotides and does not use any coupling enzymes. This innovation reduces the number of false positives and missed hits. The assay maintains a high rate of accuracy and can distinguish between nucleotides based on a single methyl group or phosphate.
BellBrook Labs' Transcreener uses a simple, three-step process and is compatible with all major multimode readers. Labs run the reaction, add Transcreener detection reagents, and then read the results. There are no additional incubation or mixing steps. Researchers can premix the reagents and store them at room temperature. In addition, BellBrook Labs guarantees that the fluorescent signals from the reaction will last overnight, and in some cases for several days. This makes it easy to automate the process and reduces the time between experimental runs. Since Transcreener allows labs to perform more tests in a shorter time period, it can speed up drug discovery.
Currently, BellBrook Labs is perfecting an RGS Protein Assay known as RGScreen. This assay is especially important to researchers who study Parkinson's disease, since drugs that inhibit the actions of the RGS4 protein may provide a new method of treating the disease. The RGScreen assay is currently available as a service and will soon be available in reagent kits, making it possible for pharmaceutical firms to quickly identify compounds which target RGS4 and other RGS proteins.